Today: 16 May 2026
Browse Category

ASX:CMM 8 January 2026

Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

The S&P/ASX 200 closed up 0.29% at 8,720.8, led by gains in tech and healthcare, while miners fell. BlueScope rejected a A$13.2 billion takeover bid from SGH and Steel Dynamics. Ansell shares dropped 6.2% as CEO Neil Salmon announced his retirement, with Nathalie Ahlström set to take over in February. The Australian dollar slipped to about 67 U.S. cents.
8 January 2026
·········

Stock Market Today

  • S&P/TSX and U.S. Markets Fall as Oil Prices Rise and Bond Yields Climb
    May 15, 2026, 6:15 PM EDT. The S&P/TSX composite dropped over 400 points to 33,833.35, led down by materials and precious metals amid rising global oil prices and inflation concerns. In the U.S., the Dow fell 537.29 points to 49,526.17, the S&P 500 lost 92.74 points to 7,408.50, and the Nasdaq slid 410.08 points to 26,225.14, pressured by tech and AI stocks. Crude oil surged to US$101.02 per barrel due to disruptions in the Strait of Hormuz, fueling inflation fears. U.S. Treasury yields rose to 2007 levels, increasing borrowing costs and pressuring equities. Investors await Canadian inflation data that may exceed 3%, influencing Bank of Canada rate expectations. The Canadian dollar edged down to 72.72 cents US, and gold prices fell sharply.

Latest articles

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

15 May 2026
Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
AXT delays annual meeting to June after AI-driven stock jump

AXT delays annual meeting to June after AI-driven stock jump

15 May 2026
AXT adjourned its 2026 annual meeting after failing to reach a quorum, rescheduling for June 4. The company seeks shareholder approval to raise authorized common shares to 120 million from 70 million. Shares closed at $123.78, up 7.65%, after a volatile session. China’s export controls on indium phosphide remain a key risk for AXT’s business.
Hyperscale Data moves higher after $5M tender, all eyes on 10-Q

Hyperscale Data moves higher after $5M tender, all eyes on 10-Q

15 May 2026
Hyperscale Data plans a tender offer to buy up to $5 million of Class A shares at $0.21 each, above the last GPUS trade at $0.146. The company reported a preliminary first-quarter net loss of about $30 million on revenue of $44 million and filed a late notice for its Form 10-Q. The offer is pending board and regulatory approval.
Go toTop